Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe (e–Pub ahead of print) (LOE Classification)

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe... Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe H.H. Feldman, MD, ABSTRACT FRCP(C) Background: There is some evidence that statins may have a protective and symptomatic benefit R.S. Doody, MD, PhD in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the M. Kivipelto, MD, PhD efficacy and safety of atorvastatin in patients with mild to moderate AD. D.L. Sparks, PhD Methods: This was an international, multicenter, double-blind, randomized, parallel-group study. D.D. Waters, MD Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13–25), were R.W. Jones, MB, FRCP aged 50 –90 years, and were taking donepezil 10 mg daily for 3 months prior to screening. E. Schwam, PhD Entry low-density lipoprotein cholesterol levels (LDL-C) were 95 and 195 mg/dL. Patients R. Schindler, MD were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, J. Hey-Hadavi, MD 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzhei- D.A. DeMicco, PharmD mer’s Disease Assessment Scale–Cognitive Subscale [ADAS-Cog]) and global function (Alzhei- A. Breazna, PhD mer’s Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 On behalf of the LEADe weeks. Investigators Results: http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurology Wolters Kluwer Health

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe (e–Pub ahead of print) (LOE Classification)

Breazna, A.
Neurology , Volume 74 (12) – Mar 1, 2010
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/randomized-controlled-trial-of-atorvastatin-in-mild-to-moderate-ZjVggLtkYX

References (44)

ISSN
0028-3878
eISSN
1526-632X
DOI
10.1212/WNL.0b013e3181d6476a
pmid
20200346
Publisher site
See Article on Publisher Site

Abstract

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe H.H. Feldman, MD, ABSTRACT FRCP(C) Background: There is some evidence that statins may have a protective and symptomatic benefit R.S. Doody, MD, PhD in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the M. Kivipelto, MD, PhD efficacy and safety of atorvastatin in patients with mild to moderate AD. D.L. Sparks, PhD Methods: This was an international, multicenter, double-blind, randomized, parallel-group study. D.D. Waters, MD Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13–25), were R.W. Jones, MB, FRCP aged 50 –90 years, and were taking donepezil 10 mg daily for 3 months prior to screening. E. Schwam, PhD Entry low-density lipoprotein cholesterol levels (LDL-C) were 95 and 195 mg/dL. Patients R. Schindler, MD were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, J. Hey-Hadavi, MD 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzhei- D.A. DeMicco, PharmD mer’s Disease Assessment Scale–Cognitive Subscale [ADAS-Cog]) and global function (Alzhei- A. Breazna, PhD mer’s Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 On behalf of the LEADe weeks. Investigators Results:

Journal

Neurology – Wolters Kluwer Health

Published: Mar 1, 2010

There are no references for this article.